Alivus Life Sciences Q2FY27 Results: Record Margins and Strong Profit Growth
Alivus Life Sciences Ltd 路 Press Release 路 30 Oct 2026, 1:03 am
Alivus Life Sciences Q2FY27 Results: Record Margins and Strong Profit Growth Alivus Life Sciences reported Q2FY27 revenue of Rs 6,820 Mn, up 16.0% YoY, led by a 20.8% YoY rise in non-GPL business. EBITDA surged 47.0% YoY to Rs 2,851 Mn with record margins of 41.8% (up 880 bps YoY, 520 bps QoQ), driven by operating leverage and favorable product mix. PAT rose 51.3% YoY to Rs 1,968 Mn. As of 30th Sep'26, cash and equivalents stood at Rs 10,116 Mn. Solapur capex remains on track for completion across Q3-Q4FY27.
Original exchange filing (PDF)
More announcements from Alivus Life Sciences Ltd
- Enclosed please find herewith update on acquisition. 路 11 Nov 2026
- Please find enclosed herewith disclosure under Regulation 30 of SEBI(LODR), 2015. 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nirma Ltd 路 07 Nov 2026
- Please find attached herewith submission with respect to transcript of the earning call. 路 06 Nov 2026
- Please find enclosed herewith intimation for Analyst/Investor meeting. 路 04 Nov 2026
- Please find enclosed herewith intimation for Analyst/Investor Meet. 路 30 Oct 2026
- We hereby confirm that we have uploaded audio recording of the Q2 FY2027 Earnings Call held on October 30, 2026 on the website of the Company. 路 30 Oct 2026
- Please find enclosed herewith intimation with respect to allotment of equity shares under "Employee Stock Option Scheme, 2021" 路 30 Oct 2026
